HCW Biologics Inc. (NASDAQ:HCWB) Sees Significant Growth in Short Interest

HCW Biologics Inc. (NASDAQ:HCWB) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 144,700 shares, a growth of 1,686.4% from the October 31st total of 8,100 shares. Currently, 0.7% of the company’s shares are sold short. Based on an average daily trading volume, of 8,960,000 shares, the days-to-cover ratio is currently 0.0 days.

HCW Biologics Stock Performance

NASDAQ:HCWB opened at $0.50 on Friday. The company has a market cap of $18.99 million, a P/E ratio of -0.50 and a beta of 0.83. The firm’s 50 day moving average is $0.53 and its two-hundred day moving average is $0.67. HCW Biologics has a fifty-two week low of $0.28 and a fifty-two week high of $2.52. The company has a quick ratio of 0.07, a current ratio of 0.07 and a debt-to-equity ratio of 0.95.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.